Cephalon’s Proposed Fentora Controls May Extend To All Rapid-Onset Opiates
Executive Summary
Cephalon aims to launch its COVERS pilot program for the pain drug Fentora later this year and says FDA is likely to require comparable enhanced risk management for its off-patent opiate Actiq and generic versions of that product
You may also be interested in...
DoJ, Congress Want Ad Oversight: FDA Sounds Ready To Respond
The Department of Justice's level of interest in drug industry promotional issues seems to be increasing, FDA Division of Drug Marketing, Advertising & Communications Director Tom Abrams told the Food & Drug Law Institute advertising and promotion conference Sept. 8
DoJ, Congress Want Ad Oversight: FDA Sounds Ready To Respond
The Department of Justice's level of interest in drug industry promotional issues seems to be increasing, FDA Division of Drug Marketing, Advertising & Communications Director Tom Abrams told the Food & Drug Law Institute advertising and promotion conference Sept. 8
The Role Of RiskMAPs: Fentora Shows Shift From Post-Market To Pre-Market
Cephalon needs to improve the risk management plan for its breakthrough cancer pain drug Fentora regardless of whether it expands use to non-cancer pain patients, according to FDA and a joint Anesthetic and Life Support Drugs and Drug Safety and Risk Management Advisory Committee